$CRVS News

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest

Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals

Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call - Slideshow

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success